HOWL

HOWL

Werewolf Therapeutics Inc

Net โ€”top 1%Rev โ€”top 1%5Y
Hold

Werewolf Therapeutics develops biopharmaceuticals to stimulate the immune system for cancer and immune-mediated conditions using its PREDATOR platform. Key products include WTX-124 and WTX-330, conditionally activated molecules targeting solid tumors.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$25today

Score Overview

1 Year
Score
Net Growth13.75%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
All Time
Score
Net Growth-22.21%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Werewolf Therapeutics Inc fundamental performance

Across Werewolf Therapeutics Inc's full reported history, from 2021 to 2025, revenue declined from $ 4M to $ 0.00 and net income went from -$ 49M to -$ 60M. Revenue increased in 50% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.38โ€”
1 Year2025-08-12
$ 1.20-68.17%
5 Years2021-08-12
$ 15.22-97.49%
All Time2021-04-30
$ 16.10-97.63%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 60M$ 57M
2024$ 1M-$ 70M$ 110M
2023$ 19M-$ 37M$ 134M
2022$ 16M-$ 51M$ 129M
IPO2021$ 4M-$ 49M$ 157M

Explore beyond HOWL

You're looking at Werewolf Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies